A patient developed monomorphic B-cell posttransplant lymphoproliferative disorder (PTLD) of immunoblastic type (Epstein-Barr virus [EBV]+) in her renal transplant 2 months after transplantation. She ...
PTLD develops in approximately 1 in 5 recipients of EBV-positive donor kidneys, a much higher rate than previously thought. Recipients of kidney transplants infected with Epstein-Barr virus (EBV) have ...
Scientists have taken a major step toward stopping Epstein-Barr virus (EBV), an extremely common infection linked to cancer ...
Central nervous system (CNS) PTLD generally carries a dismal prognosis. It is seen in both children and adults and about half of cases occur in isolation, with the rest occurring in the setting of ...
Monitoring Epstein-Barr virus (EBV) levels after liver transplantation to avoid over-immunosuppression showed a signal for less post-transplant lymphoproliferative disease (PTLD) over the long term in ...
The occurrence of post-transplant lymphoproliferative disorder (PTLD) in relation to immunosuppressive treatment was determined in 257 patients treated with non-T-cell-depleted allogeneic stem cell ...
The US Food and Drug Administration (FDA) has accepted the biologics licence application (BLA) and granted priority review for Pierre Fabre Pharmaceuticals’ Tabelecleucel (Tab-cel) to treat ...
Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study Eligible patients received cyclophosphamide (600 mg/m 2 ...
Does Epstein-Barr virus (EBV) prophylaxis lower the risk of post-transplantation lymphoproliferative disorder (PTLD)? Investigations conducted to date, often involving small populations or historical ...
Transplants can trigger EBV reactivation, leading to EBV-positive PTLD, with poor survival if rituximab fails. Tabelecleucel (tab-cel) shows promise in treating refractory EBV+ PTLD, with significant ...
Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study Eligible patients received cyclophosphamide (600 mg/m 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results